Ubidecarenone

Identification

Are you a

new drug developer?

Contact us to learn more about our customized products and solutions.

Name

Ubidecarenone

Accession Number

DB09270

Type

Small Molecule

Groups

Approved, Investigational, Nutraceutical

Description

Ubidecarenone, also called coenzyme Q10, is a 1,4-benzoquinone. From his name (Q10), the Q refers to the constitutive quinone group, and 10 is related to the number of isoprenyl subunits in its tail.¹ It is a powerful antioxidant, a lipid-soluble and essential cofactor in mitochondrial oxidative phosphorylation.² The ubidecarenone is the coenzyme destined for mitochondrial enzyme complexes involved in oxidative phosphorylation in the production of ATP. It is fundamental for cells that have a high metabolic demand.⁷ Ubidecarenone is sold as a dietary supplement and is not FDA approved as a drug thus, it is not meant to treat, cure or prevent any disease. FDA does not approve this dietary supplements before sold nor regulate the manufacturing process.⁸

Structure

Download

MOLSDFPDBSMILESInChI

Similar Structures

Structure for Ubidecarenone (DB09270)

×

Close

Synonyms

• Coenzyme Q-10
• Coenzyme Q10
• Ubidecarenone

External IDs

API 31510 / API-31510 / NSC-140865

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Coenzyme q10, (2z)-	U705VLF0VW	65085-29-2	ACTIUHUUMQJHFO-LLOLQPSSSA-N

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Unlock Additional Data
Co-enzyme Q-10 Capsules	Capsule	30 mg	Oral	Ashbury Research Corporation	Not applicable	Not applicable
Co-q10 (ubiquinone)	Capsule	60 mg	Oral	Abundance Naturally Ltd	Not applicable	Not applicable
Q-gel Coenzyme Q10	Capsule	15 mg	Oral	T & T Nutrition Inc.	Not applicable	Not applicable
Watkins Coq10	Tablet	60 mg	Oral	Watkins Incorporated	Not applicable	Not applicable

Additional Data Available

Application Number
Application Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more
Product Code
Product Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Unlock Additional Data
Acti-ubiquinone 50 Cap 50mg	Capsule	50 mg	Oral	Acti Form Ltd.	1991-12-31	2005-03-21
Biogard Ubiquinone Cap 30mg	Capsule	30 mg	Oral	Sisu Inc.	1994-12-31	2001-08-01
Biomed Co Q 10	Capsule	100 mg	Oral	Sisu Inc.	1998-02-11	2008-07-25
Cell Tech Coenzyme Q10 - Cap 30mg	Capsule	30 mg	Oral	Cell Tech	1996-11-12	2000-10-05
Cellsparc 360	Capsule	60 mg	Oral	Aim International, Inc.	1998-07-29	2008-09-03
Co Q 10 - 50mg Cap	Capsule	50 mg	Oral	Albi Naturals	1994-12-31	2008-07-17
Co-enzyme Q-10	Capsule	30 mg	Oral	Holista Health (Canada) Inc.	1996-12-31	2002-08-06
Co-enzyme Q-10	Capsule	30 mg	Oral	Seroyal International Inc.	1995-12-31	2008-07-14
Co-enzyme Q10 100mg	Capsule	100 mg	Oral	Natural Factors Nutritional Products Ltd.	1999-07-12	2009-09-28
Co-enzyme Q10 30mg Capsules	Capsule	30 mg	Oral	Alive Vitamins	1998-07-27	2005-07-04

Additional Data Available

Application Number
Application Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more
Product Code
Product Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Biosculpt	Ubidecarenone (1.5 mg) + Choline bitartrate (0.3 mg) + Chromium (40 mcg) + Inositol (0.3 mg) + Calcium pantothenate (60 mg) + Pyridoxine hydrochloride (4 mg)	Solution	Oral	Maxion Nutrition Corp.	2002-06-10	2004-07-20
C.V. Formula	Ubidecarenone (30 mg) + Vitamin E (30 unit)	Liquid	Oral	Morinda Canada	2001-06-27	2005-07-13
Co-q10 and Vitamin E	Ubidecarenone (100 mg) + alpha-Tocopherol succinate (300 unit)	Capsule	Oral	Biomed International Products Corp.	2003-10-01	2006-06-29
Co-q10 M.R.B. 100mg and Vitamin E	Ubidecarenone (100 mg) + Vitamin E (150 unit)	Capsule	Oral	Inno Vite Incorporated	2004-01-23	2007-07-31
Co-q10 M.R.B. 60mg	Ubidecarenone (60 mg) + Vitamin E (150 unit)	Capsule	Oral	Inno Vite Incorporated	2003-09-17	2007-07-31
Coen.q10w.vit.c and E Beta-car.se Cu Zn Mn	Ubidecarenone (10 mg) + Ascorbic acid (300 mg) + Beta carotene (5000 unit) + Copper (1 mg) + D-alpha-Tocopherol acetate (200 unit) + Manganese (5 mg) + Selenium (15 mcg) + Zinc (5 mg)	Capsule	Oral	Jamieson Laboratories Ltd	1995-12-31	2001-09-14
Coenzyme Q10 +	Ubidecarenone (30 mg) + Vitamin E (30 mg)	Capsule	Oral	Body Wise International Llc	Not applicable	Not applicable
Coenzyme Q10 Isotonix Vitamin and Mineral Supplement	Ubidecarenone (30.03 mg) + Potassium (32.43 mg) + Riboflavin (0.9 mg) + alpha-Tocopherol acetate (60.06 mg)	Powder	Oral	Market America	2002-06-04	2008-09-04
Coq10 With E400 Iu	Ubidecarenone (30 mg) + Vitamin E (400 unit)	Capsule	Oral	Pharmavite	1999-09-15	2004-07-20
Daily Supplement Packs	Ubidecarenone (30 mg) + Cyanocobalamin (125 mcg) + Folic Acid (0.4 mg) + Magnesium (150 mg) + Pyridoxine (50 mg) + Vitamin E (400 unit)	Capsule	Oral	Wn Pharmaceuticals Ltd.	2002-10-18	2005-08-15

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Dyzbac	Ubidecarenone (50 mg/1) + Ascorbic acid (150 mg/1) + Cholecalciferol (0.0125 mg/1) + Leucovorin (1 mg/1) + Lipoic Acid (125 mg/1) + Methylcobalamin (1 mg/1) + Pyridoxal phosphate (12.5 mg/1) + Resveratrol (50 mg/1)	Tablet	Oral	Basiem	2015-10-28	2015-11-01
Dyzbac	Ubidecarenone (25 mg/1) + Ascorbic acid (125 mg/1) + Cholecalciferol (500 [iU]/1) + Leucovorin (1 mg/1) + Lipoic Acid (150 mg/1) + Methylcobalamin (1 mg/1) + Pyridoxal phosphate (12.5 mg/1) + Resveratrol (50 mg/1)	Tablet	Oral	Basiem	2015-11-05	2016-01-01
IQQU Acne Serum	Ubidecarenone (0.0012 g/1g) + Lecithin, soybean (0.024 g/30g) + Levocarnitine (0.012 g/1g)	Lotion	Topical	Iqqu Usa Co.	2009-08-01	Not applicable
Lexazin	Coenzyme q10, (2z)- (50 mg/1) + Ascorbic acid (125 mg/1) + Cholecalciferol (500 [iU]/1) + Folic Acid (1 mg/1) + Methylcobalamin (5 mg/1) + NADH (5 mg/1) + Pyridoxal phosphate (12.5 mg/1) + Thiamine hydrochloride (25 mg/1)	Capsule	Oral	Sterling Knight Pharmaceuticals, Llc	2018-01-02	2018-10-31
Mebolex	Ubidecarenone (25 mg/1) + Ascorbic acid (125 mg/1) + Cholecalciferol (0.0125 mg/1) + Leucovorin (1 mg/1) + Lipoic Acid (150 mg/1) + Methylcobalamin (1 mg/1) + Pyridoxal phosphate (12.5 mg/1) + Resveratrol (50 mg/1)	Tablet	Oral	Solubiomix	2015-10-28	2016-01-01
Medi-10	Ubidecarenone (16 mg/1) + Acetylcysteine (200 mg/1) + Cholecalciferol (1000 [iU]/1) + Chromium picolinate (1 mg/1) + Levomefolate calcium (2.5 mg/1) + Lipoic Acid (200 mg/1) + Methylcobalamin (2.5 mg/1) + Nicotinamide (10 mg/1) + Pyridoxal phosphate (20 mg/1) + Resveratrol (83 mg/1)	Capsule	Oral	Medicap Laboratories Inc.	2015-05-01	2016-01-12
Methazel	Coenzyme q10, (2z)- (25 mg/1) + Acetylcysteine (50 mg/1) + Folic Acid (1 mg/1) + Lipoic Acid (50 mg/1) + Methylcobalamin (2.5 mg/1) + Pyridoxal phosphate (50 mg/1)	Capsule	Oral	Sterling-Knight Pharmaceuticals, LLC	2015-10-12	Not applicable
PreQue 10	Ubidecarenone (50 mg/1) + Ascorbic acid (30 mg/1) + Cholecalciferol (120 [iU]/1) + Cupric oxide (1 mg/1) + Cyanocobalamin (1 ug/1) + Doconexent (50 mg/1) + Docusate sodium (25 mg/1) + Folic Acid (0.5 mg/1) + Iron (15 mg/1) + Lycopene (5 mg/1) + Magnesium oxide (10 mg/1) + Riboflavin (1.7 mg/1) + Selenium (7.5 ug/1) + Thiamine chloride (1 mg/1) + Vitamin A (1250 [iU]/1) + Vitamin E (15 [iU]/1) + Zinc oxide (12.5 mg/1)	Tablet	Oral	Actavis Pharma Company	2011-11-01	2018-06-05
PreQue 10	Ubidecarenone (50 mg/1) + Ascorbic acid (30 mg/1) + Cholecalciferol (120 [iU]/1) + Cupric oxide (1 mg/1) + Cyanocobalamin (1 ug/1) + Doconexent (50 mg/1) + Docusate sodium (25 mg/1) + Folic Acid (0.5 mg/1) + Iron (15 mg/1) + Lycopene (5 mg/1) + Magnesium oxide (10 mg/1) + Riboflavin (1.7 mg/1) + Selenium (7.5 ug/1) + Thiamine mononitrate (1 mg/1) + Vitamin A (1250 [iU]/1) + Zinc oxide (12.5 mg/1) + alpha-Tocopherol succinate (15 [iU]/1)	Tablet	Oral	Physicians Total Care, Inc.	2011-11-01	2013-02-11
Vita-Rx Diabetic Vitamin	Ubidecarenone (50 mg/1) + Ascorbic acid (120 mg/1) + Biotin (2.5 mg/1) + Cholecalciferol (0.0625 mg/1) + Chromium picolinate (0.465 mg/1) + Folic Acid (0.8 mg/1) + Lipoic Acid (150 mg/1) + Methylcobalamin (0.0025 mg/1) + Niacin (20 mg/1) + Calcium pantothenate (10 mg/1) + Pyridoxal phosphate (12.5 mg/1) + Riboflavin (1.7 mg/1) + Thiamine mononitrate (1.5 mg/1) + alpha-Tocopherol acetate (10 mg/1)	Capsule, gelatin coated	Oral	Pure Source, Llc	2015-08-11	Not applicable

Categories

• Agents Causing Muscle Toxicity
• Benzoquinones
• Cardiac Therapy
• Coenzymes
• Diet, Food, and Nutrition
• Electron Transport Chain Complex Proteins
• Enzymes and Coenzymes
• Food
• Food and Beverages
• Growth Substances
• Hypoglycemia-Associated Agents
• Micronutrients
• Other Nutritional Agents
• P-glycoprotein/ABCB1 Substrates
• Physiological Phenomena
• Quinones
• Vitamins

UNII

EJ27X76M46

CAS number

303-98-0

Weight

Average: 863.3435
Monoisotopic: 862.683911368

Chemical Formula

C₅₉H₉₀O₄

InChI Key

ACTIUHUUMQJHFO-UPTCCGCDSA-N

InChI

InChI=1S/C59H90O4/c1-44(2)24-15-25-45(3)26-16-27-46(4)28-17-29-47(5)30-18-31-48(6)32-19-33-49(7)34-20-35-50(8)36-21-37-51(9)38-22-39-52(10)40-23-41-53(11)42-43-55-54(12)56(60)58(62-13)59(63-14)57(55)61/h24,26,28,30,32,34,36,38,40,42H,15-23,25,27,29,31,33,35,37,39,41,43H2,1-14H3/b45-26+,46-28+,47-30+,48-32+,49-34+,50-36+,51-38+,52-40+,53-42+

IUPAC Name

2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-yl]-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione

SMILES

COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O

Pharmacology

Indication

The diet supplements containing ubidecarenone are indicated, as stated in the product label, to assist individuals with cardiovascular complaints including congestive heart failure and systolic hypertension. In the product, ubidecarenone is used to increase the cardiac input as well as for the prevention of several other diseases like Parkinson, fibromyalgia, migraine, periodontal disease and diabetes, based on preclinical studies.⁹ It is important to highlight that these products are not FDA approved and it is recommended to use under discretion.

Associated Conditions

• Migraine

Pharmacodynamics

Ubidecarenon has roles in many prysiological process including sulfide oxidation, regulation of mitochondrial permeability transition pore and translocation of protons and calcium ions accross biological membranes. Studies have shown its benefitial effect in treating cancer, statin myopathy, congestive heart failure and hypertension.²

Mechanism of action

Ubidecarenone is an essential cofactor in the mitochondrial electron transport chain. Its functions are the acceptance of electrons from the complex I and II and this activity is vital for the production of ATP. It acts as a mobile redox agent shuttling electrons and protons in the electron transport chain.⁵ Ubidecarenone also presents antioxidant activity in mitochondria and cellular membranes, protecting against peroxidation of lipid membranes as well as inhibiting oxidation of LDL-cholesterol.¹⁰

Target	Actions	Organism
ANADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial	cofactor	Humans
ASuccinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial	cofactor	Humans

Unlock Additional Data

Additional Data Available

Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more

Additional Data Available

Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more

Additional Data Available

Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more

Absorption

Ubidecarenone is absorbed from the small intestine into the lymphatics and then it can enter the blood. The hydrophobicity and large molecular weight limit its absorption making it very poor and variable depending on the food intake and the number of lipids presented in the food. The absorption is lower in the presence of an empty stomach and greater in presence of high lipid food diet. The daily dosage of ubidecarenone presents the reach of maximal serum concentration by reaching a plateau after three weeks.¹⁰ The pharmacokinetic properties may vary between different brands but studies have reported an AUC of 11.51 mcg h/ml and a Cmax of 0.32 mcg/ml at a time of 7.9 h.³

Volume of distribution

Ubidecarenone is distributed to the various tissues of the body and it is able to enter the brain.¹⁰ In preclinical studies with intravenous administration of ubidecarenone, it is reported a volume of distribution of 20.4 L/kg which reflects its ability to penetrate extensively into organs and tissues.⁴ AS a general rule, tissues with high-energy requirements or metabolic activity tend to presents higher amounts of ubidecarenone, these organs can be heart, kidney, liver and muscle.⁵

Protein binding

In the blood, ubidecarenone is split into the various lipoprotein particles including LDL and VLDL.¹⁰ The plasma concentration of ubidecarenone is highly dependent on the presence of plasma lipoproteins and about 95% of the administered form is found in the reduced form.⁵

Metabolism

Studies indicate that there is no saturation process during the metabolism of ubidecarenone. It is metabolized in all tissues by the phosphorylation in the cells and transportation to the kidneys for further excretion by the urine.¹¹ After exerting its action, ubidecarenone is reduced and forms hydroquinone which is capable of recycling and regenerates other antioxidants such as tocopherol and ascorbate. The later metabolism of hydroquinone generates the formation of Q acid I and Q acid II in free and conjugated forms.⁵

Route of elimination

The main elimination route of ubidecarenone is through the bile. After its oral administration, over 60% of the dose is excreted in the feces in the form of unchanged ubidecarenone and a small fraction of the metabolites.^10,5 In the urine, ubidecarenone is bound to saposin B protein and represents only 8.3% of the total administered dose.⁵

Half life

The pharmacokinetic properties may vary between different brands but studies have reported a half-life of ubidecarenone of 21.7 h.³

Clearance

In preclinical studies with intravenous administration of ubidecarenone, it is reported a total clearance of 1.18 ml h/kg which was indicative of a prolonged elimination.⁴

Toxicity

There have not been reports of adverse events of diet supplementation with ubidecarenone.⁶ The normal side effects reported in humans are related to the gastrointestinal tract.⁵

Affected organisms

• Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

• All Drugs
• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental

Drug	Interaction
Unlock Additional Data
(R)-warfarin	The therapeutic efficacy of (R)-warfarin can be decreased when used in combination with Ubidecarenone.
(S)-Warfarin	The therapeutic efficacy of (S)-Warfarin can be decreased when used in combination with Ubidecarenone.
2,4-thiazolidinedione	The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with 2,4-thiazolidinedione.
4-hydroxycoumarin	The therapeutic efficacy of 4-hydroxycoumarin can be decreased when used in combination with Ubidecarenone.
Abemaciclib	The serum concentration of Ubidecarenone can be increased when it is combined with Abemaciclib.
Acarbose	The risk or severity of hypoglycemia can be increased when Acarbose is combined with Ubidecarenone.
Acebutolol	The serum concentration of Ubidecarenone can be increased when it is combined with Acebutolol.
Acenocoumarol	The therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Ubidecarenone.
Acetaminophen	The serum concentration of Ubidecarenone can be increased when it is combined with Acetaminophen.
Acetohexamide	The risk or severity of hypoglycemia can be increased when Ubidecarenone is combined with Acetohexamide.

Additional Data Available

Extended Description
Extended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more
Severity
Severity
A severity rating for each drug interaction, from minor to major.
Learn more
Evidence Level
Evidence Level
A rating for the strength of the evidence supporting each drug interaction.
Learn more
Action
Evidence Level
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more

Food Interactions

Not Available

References

General References

1. Ernster L, Dallner G: Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. 1995 May 24;1271(1):195-204. [PubMed:7599208]
2. Xue R, Yang J, Wu J, Meng Q, Hao J: Coenzyme Q10 inhibits the activation of pancreatic stellate cells through PI3K/AKT/mTOR signaling pathway. Oncotarget. 2017 Sep 23;8(54):92300-92311. doi: 10.18632/oncotarget.21247. eCollection 2017 Nov 3. [PubMed:29190916]
3. Kang EY, Choi JW, Gwak HS, Chun IK: Comparison of bioavailability of two ubidecarenone products in healthy Korean volunteers. Int J Clin Pharmacol Ther. 2009 Mar;47(3):207-14. [PubMed:19281730]
4. Kalenikova EI, Gorodetskaya EA, Medvedev OS: Pharmacokinetics of coenzyme q10. Bull Exp Biol Med. 2008 Sep;146(3):313-6. [PubMed:19240848]
5. Bhagavan HN, Chopra RK: Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res. 2006 May;40(5):445-53. doi: 10.1080/10715760600617843. [PubMed:16551570]
6. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M: Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002 Oct;59(10):1541-50. [PubMed:12374491]
7. FDA Reports [Link]
8. Pubmedhealth [Link]
9. Diet supplement label [Link]
10. Coenzyme Q [Link]
11. Journal of Health Science [Link]

External Links

Human Metabolome Database

HMDB0001072

KEGG Drug

D01065

KEGG Compound

C11378

PubChem Compound

5281915

PubChem Substance

310265165

ChemSpider

4445197

ChEBI

46245

ChEMBL

CHEMBL454801

HET

U10

Wikipedia

Coenzyme_Q10

ATC Codes

C01EB09 — Ubidecarenone

• C01EB — Other cardiac preparations
• C01E — OTHER CARDIAC PREPARATIONS
• C01 — CARDIAC THERAPY
• C — CARDIOVASCULAR SYSTEM

AHFS Codes

• 88:30.00* — Other Nutritional Agents

PDB Entries

1aig / 1aij / 1bcc / 1ds8 / 1dv3 / 1dv6 / 1e14 / 1e6d / 1f6n / 1fnp …

show 93 more

MSDS

Download (92.4 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Active Not Recruiting	Supportive Care	Cancer, Breast	1
1	Completed	Basic Science	Healthy Volunteers	1
1	Completed	Supportive Care	Sporadic Ataxia	1
1, 2	Completed	Supportive Care	Charcot Marie Tooth Disease	1
1, 2	Completed	Treatment	Squamous Cell Carcinoma (SCC)	1
1, 2	Completed	Treatment	Superficial Basal Cell Carcinoma	1
1, 2	Terminated	Supportive Care	Quality of Life	1
2	Active Not Recruiting	Treatment	Malignant Neoplasm of Pancreas	1
2	Completed	Treatment	Amyotrophic Lateral Sclerosis (ALS) / Lou Gehrig's Disease	1
2	Completed	Treatment	Cardiac Arrest / Sudden Cardiac Arrest	1
2	Completed	Treatment	Huntington's Disease (HD)	1
2	Completed	Treatment	Muscular Dystrophy, Duchenne	1
2	Completed	Treatment	NPDR - Non Proliferative Diabetic Retinopathy / Type 2 Diabetes Mellitus	1
2	Completed	Treatment	Parkinson's Disease (PD)	2
2	Completed	Treatment	Progressive Supranuclear Palsy (PSP)	1
2	Not Yet Recruiting	Treatment	Heart Failure	1
2	Recruiting	Treatment	Heart Failure, Diastolic	1
2	Withdrawn	Not Available	Bipolar Affective Disorders / Depression	1
2	Withdrawn	Treatment	Squamous Cell Carcinoma (SCC)	1
2, 3	Completed	Treatment	Atypical Parkinsonism / Progressive Supranuclear Palsy (PSP)	1
2, 3	Completed	Treatment	Becker's Muscular Dystrophy (BMD) / Duchenne's Muscular Dystrophy (DMD) / Limb Girdle Muscular Dystrophy	1
2, 3	Completed	Treatment	Neurological Disorders / Progressive Supranuclear Palsy (PSP)	1
3	Terminated	Treatment	Huntington's Disease (HD)	1
4	Completed	Treatment	Chronic Renal Failure (CRF) / Hemodialysis Treatment	1
4	Completed	Treatment	Congestive Cardiomyopathy	1
4	Completed	Treatment	Muscle Soreness / Muscle Weakness / Side Effects of Statins	1
4	Withdrawn	Treatment	Idiopathic Infertility	1
Not Available	Completed	Basic Science	Depression, Bipolar	2
Not Available	Completed	Treatment	Polycystic Ovaries Syndrome	1
Not Available	Not Yet Recruiting	Treatment	Oral Aphthous Ulcer	1
Not Available	Unknown Status	Basic Science	Statin Myopathy	1
Not Available	Unknown Status	Treatment	Coenzyme Q10 on Athero-thrombosis in APS Patients	1
Not Available	Unknown Status	Treatment	Congestive Heart Failure (CHF)	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Form	Route	Strength
Capsule	Oral	50 mg
Capsule	Oral	100 mg
Solution	Oral
Liquid	Oral
Tablet	Oral	10 mg
Capsule	Oral	50.0 mg
Capsule	Oral	12 mg
Tablet	Oral	100 mg
Capsule	Oral	60 mg
Capsule	Oral	80 mg
Capsule	Oral	15 mg
Capsule	Oral	30 mg
Powder	Oral
Capsule	Oral	10 mg
Capsule	Oral
Lotion	Topical
Tablet	Oral
Tablet	Oral	60 mg
Capsule	Oral	25 mg
Capsule	Oral	20 mg
Capsule, gelatin coated	Oral

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	50-52ºC	MSDS
water solubility	Sparingly soluble	MSDS
logP	10	Lucangioli S. and Tripodi V., Der Pharmacia Sinica, (2012), 3 (4):406-407

Predicted Properties

Property	Value	Source
Water Solubility	0.000193 mg/mL	ALOGPS
logP	9.94	ALOGPS
logP	17.16	ChemAxon
logS	-6.6	ALOGPS
pKa (Strongest Basic)	-4.7	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	4	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	52.6 Å2	ChemAxon
Rotatable Bond Count	31	ChemAxon
Refractivity	286.61 m3·mol-1	ChemAxon
Polarizability	112.38 Å3	ChemAxon
Number of Rings	1	ChemAxon
Bioavailability	0	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	splash10-03dj-0211112090-13e67655f61e48a95d91
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	splash10-00kb-0859598220-67d1d2437197bf4977c9
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	splash10-014j-1132229710-87eed3c798b1c43399ec
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	splash10-03di-0000000090-68b5c91d1736a6033778
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	splash10-08fs-0100000390-3f2c6d6cc684a14c6586
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	splash10-000b-8100000890-af49da707a25798624ae

Taxonomy

Description

This compound belongs to the class of organic compounds known as ubiquinones. These are coenzyme Q derivatives containing a 5, 6-dimethoxy-3-methyl(1,4-benzoquinone) moiety to which an isoprenyl group is attached at ring position 2(or 6).

Kingdom

Organic compounds

Super Class

Lipids and lipid-like molecules

Class

Prenol lipids

Sub Class

Quinone and hydroquinone lipids

Direct Parent

Ubiquinones

Alternative Parents

Polyterpenoids / Polyprenylbenzoquinones / P-benzoquinones / Vinylogous esters / Organic oxides / Hydrocarbon derivatives

Substituents

Polyterpenoid / Polyprenylbenzoquinone / Ubiquinone skeleton / Quinone / P-benzoquinone / Vinylogous ester / Cyclic ketone / Ketone / Organic oxygen compound / Organic oxide

Molecular Framework

Aliphatic homomonocyclic compounds

External Descriptors

ubiquinones (CHEBI:46245) / ubiquinones, Coenzymes (C11378) / Ubiquinones (LMPR02010001)

×

Unlock Data

There is additional data available for commercial users including Adverse Effects, Contraindications, and Blackbox Warnings. Contact us to learn more about these and other features.

Learn more

Drug created on October 28, 2015 09:41 / Updated on May 21, 2019 12:25